NKNatalia Krześniak

Natalia Krześniak

*This is an algorithmically generated author record based on publicly available information.

Natalia Krześniak has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Aneta Ścieżyńska

    Laboratory of Molecular Oncology and Innovative Therapies, Military Institute of Medicine National Research Institute, 128 Szaserów Street, 04-141 Warsaw, Poland

    1 shared publication
  • Anna Figiel-Dabrowska

    Mossakowski Medical Research Center, Polish Academy of Sciences, Warsaw, Poland

    1 shared publication
  • Anna Lutyńska

    Department of Medical Biology, National Institute of Cardiology, 04-628 Warsaw, Poland

    1 shared publication
  • Anna Sarnowska

    Mossakowski Medical Research Center, Polish Academy of Sciences, Warsaw, Poland

    1 shared publication
  • Anna Sarnowska

    Translational Platform for Regenerative Medicine, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawinskiego 5 Street, 02-106 Warsaw, Poland

    1 shared publication
  • Anna Sobiepanek

    Laboratory of Biomolecular Interactions Studies, Chair of Drug and Cosmetics Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland

    1 shared publication

Latest Publications

  • Open Access

    Enhancing the clinical potential: Quality assessment of adipose tissue-derived Mesenchymal Stem/Stromal Cells for therapeutic use

    by Monika Rytel, Magdalena Chodkowska-Michalowska, Dorota Sulejczak, Natalia Krześniak, Marzena Zychowicz, Anna Sarnowska


  • Open Access

    Long‐Term Follow‐Up After the Charles Procedure: Possibilities for Minimally Invasive Reconstructive Lymphedema Surgery With Lymphaticovenous Anastomosis: A Report of Four Cases

    by Natalia Ewa Krzesniak, Marzanna Zaleska, Balazs Mohos, Manon Czedik‐Eysenberg, Michaela Krammel, Chieh‐Han John Tzou

    The Charles procedure (CP) is a potentially devastating treatment; however, in cases of an end stage of untreated or improperly treated lymphedema, it is the ultimate surgical therapy. As a life‐saving solution, it quickly relieves patients with giant, hypertrophic extremities, mostly in ambulation and hygiene maintenance. Nevertheless, long‐term results may disappoint both doctors and patients, who struggle with social stigma, the need for lifelong compression, massive lymphoedema in the distal parts of the feet, badly fitting shoes, excessive skin fibrosis, severe keratinization of skin‐grafted surfaces, periodic lymphorrhea from the resected areas, or acute and chronic inflammation. For these reasons, patients may seek further surgical help, even many years after treatment. This article describes findings in fluorescent lymphography with indocyanine green (ICG‐L) in four patients (49, 56, 56 years old females and 35 years old males) after CP and outcomes of treatment with lymphaticovenous anastomosis (LVA). In all patients, nonresected areas of the dorsum of the feet showed massive lymphedema stage II to III with dermal backflow (DB). In two patients, resected and skin‐grafted areas showed deep subfascial lymphatics with lazy flow and no DB. In the remaining two cases, resected areas showed massive DB. Patients were reluctant to undergo further extensive surgical treatment with lymph node transfers due to the trauma experienced after CP. Since they still struggle with residual lower extremity lymphedema in unresected areas of the lower limbs, we performed minimally invasive, physiologic LVA surgeries in their feet, and in one patient in proximal thighs. In all cases, the postoperative course was uneventful. The treatment brought relief, reducing the circumference of the feet by ~2 cm, and allowed the return to previously used shoes in a follow‐up of 18–36 months. This is the first report of ICG‐L findings in CP patients, who benefit from minimal invasive LVA surgery. This information might help improve the life quality of patients after CP.


  • Open Access

    Role of geneticin in isolation and culturing of skin melanocytes and melanoma cells

    by Aneta Ścieżyńska, Anna Sobiepanek, Marta Soszyńska, Krzysztof Łuszczyński, Marcin Radziszewski, Iryna Levkovych, Natalia Krześniak, Beata Orzechowska, Anna Lutyńska, Jacek Malejczyk

    Introduction: Development of an effective, suitable, and reliable method for both the isolation and culturing of melanocytes is crucial for studies on pathomechanisms of skin diseases originating from melanocyte disorders. In this study, we have investigated the influence of geneticin (G418), a substance used for melanocyte selection, in the view of the frequency of presence of cells such as keratinocytes and fibroblasts, widely known as contaminators of melanocyte-originating cell cultures. Materials and Methods: Study was conducted on primary, freshly isolated melanocytes, keratinocytes, fibroblasts, and melanoma cells as well as on commercially available melanoma cell lines MeWo, G-361, and A375. Cells were cultured in different culture media supplemented with various concentrations of geneticin ranging from 0.05 to 1 mg/mL. Cell viability, proliferation rate and detection of apoptotic/necrotic cells was assessed. Results: Choice of culture media supplemented with various concentrations of geneticin (0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL and 1 mg/mL) strongly affect viability of melanocytes, fibroblasts, and keratinocytes. Selective culture media without FBS facilitate the process of melanocytes and melanoma pure cell culture, yet without geneticin supplementation are insufficient for complete eradication of fibroblast contamination from cell culture. Conclusions: In this study we provide, for the first time, the dose-response action of keratinocytes and fibroblasts upon geneticin stimulation in different culture media and show that a low concentration (0.05 mg/mL) of geneticin added to the selective culture media may be safely implemented to facilitate the production of melanocyte and melanoma cell cultures that are free from frequent cell contaminants.

  • Open Access

    Secondary release of the peripheral nerve with autologous fat derivates benefits for functional and sensory recovery

    by Natalia E. Krzesniak, Anna Sarnowska, Anna Figiel-Dabrowska, Katarzyna Osiak, Krystyna Domanska-Janik, Bartłomiej H. Noszczyk

    The reconstruction of nerve continuity after traumatic nerve injury is the gold standard in hand surgery. Immediate, tension-free, end-to-end nerve suture ensures the best prognosis. The recovery is mostly promising; however, in a few cases, insufficient outcomes in motor or sensory function are observed. Intra- and extra-fascicular scarring accompanies the nerve regeneration process and limits final outcomes. Secondary nerve release in those cases is recommended. Unfortunately, scarring recurrence cannot be eliminated after secondary revision and neurolysis. The supportive influences of mesenchymal stem cells in the process of nerve regeneration were observed in many preclinical studies. However, a limited number of studies in humans have analyzed the clinical usage of mesenchymal stem cells in peripheral nerve reconstruction and revisions. The objective of this study was to evaluate the effects of undifferentiated adipose-derived stromal/stem cell injection during a last-chance surgery (neurolysis, nerve release) on a previously reconstructed nerve. Three patients (one female, two males; mean age 59 ± 4.5 years at the time of injury), who experienced failure of reconstructions of median and ulnar nerves, were included in this study. During the revision surgery, nerve fascicles were released, and adipose-derived stromal/stem cells were administered through microinjections along the fascicles and around the adjacent tissues after external neurolysis. During 36 months of follow-up, patients noticed gradual signs of sensory and in consequence functional recovery. No adverse effects were observed. Simultaneous nerve release with adipose-derived stromal/stem cells support is a promising method in patients who need secondary nerve release after nerve reconstruction. This method can constitute an alternative procedure in patients experiencing recovery failure and allow improvement in cases of limited nerve regeneration. The study protocol was approved by the Institutional Review Board (IRB) at the Centre of Postgraduate Medical Education (No. 62/PB/2016) on September 14, 2016.